Veeva Systems Fiscal Q2 2027 Earnings: Record CRM Execution Meets an Early AI Opportunity

Veeva Systems reported fiscal second-quarter revenue of $928M and non-GAAP operating income of $416M, both ahead of management’s prior guidance. The quarter’s operating message was particularly strong in Commercial Cloud, where subscription revenue grew about 13% year over year and CRM execution remained a central driver.

The larger investment question is whether Veeva can translate strong demand for AI-enabled workflows into a scalable new revenue category. Management described substantial early interest in Falcon, its agentic-labor offering, but emphasized that product readiness and successful early deployments, rather than demand, are currently the limiting factors.

As Reported on the Call

The Bigger Story

Veeva’s near-term performance remains anchored in its established Commercial and R&D software franchises, but management increasingly framed the company’s next growth chapter around AI. Falcon represents a departure from Veeva’s traditional model of selling cloud applications, data, and consulting services: management characterized it as “agentic labor,” or software agents performing defined business workflows.

That creates a potentially meaningful strategic opportunity because Falcon is being targeted at the same functional buyers Veeva already serves in clinical, regulatory, safety, and related life-sciences workflows. Management believes this existing customer access and domain-specific application footprint give Veeva an advantage over narrower AI vendors.

However, Falcon remains early. Management said Veeva is the current “rate limiter” because it must finalize the product, work through early-adopter deployments, and establish a repeatable go-to-market model. The opportunity may be significant, but revenue contribution is not yet part of Veeva’s plans, and management did not provide a timeline or financial target.

Revenue and Operating Performance

Commercial Cloud was the clearest source of momentum in the quarter. Commercial subscription revenue increased approximately 13% year over year, and management said the rest of the segment still produced double-digit growth after excluding Crossix, Veeva’s measurement and data business.

The strength was broad rather than concentrated in one product. Management cited continued CRM growth, new customers and add-ons, content applications, Data Cloud products, Crossix measurement and audience offerings, and Ostro. That breadth matters because it suggests Commercial Cloud growth was not solely dependent on a single product cycle or acquisition.

CRM was a major contributor. Chief Executive Officer Peter Gassner called the period Veeva’s best CRM quarter ever, while management said more than 180 customers are now live on Vault CRM. It also cited three large-company Vault CRM selections during the quarter, including two top-20 biopharma companies, and named Biogen and Regeneron among recent wins.

The company’s CRM positioning has become more consequential as some large customers previously elected to move to Salesforce. Management said those projects have encountered delays and implementation challenges, although this was management commentary rather than a quantified market result. Veeva believes some customers could reconsider their decisions in 2027 and 2028, ahead of the end of the Veeva CRM backstop in 2029.

That potential win-back opportunity should not be treated as booked business. Still, Veeva’s ability to get customers live on Vault CRM, including one top-20 company that has enabled CRM AI across its entire field force, strengthens its argument that its product is further along in deployment than competing alternatives.

In R&D Cloud, management described a transition in the product mix. Established applications such as eTMF, CTMS, quality documents, quality management, and regulatory products have supported historical growth. The next set of growth products includes EDC, eCOA, RTSM, Safety, and LIMS.

Management characterized those newer products as large and strategic but still early in their adoption curves. This creates a timing issue: the newer growth products may not scale at the same pace as the more mature product lines, and management said the mismatch between those “S curves” is reflected in its outlook for the remainder of fiscal 2027.

Profitability and Margins

Veeva generated $416M of non-GAAP operating income on $928M of revenue, equivalent to a non-GAAP operating margin of roughly 45%. That remains a high level of profitability while the company continues to invest in product development and new markets.

Management indicated that investment in Aspen, its new horizontal CRM initiative, is small relative to Veeva’s overall scale. It also said Falcon-related spending is already incorporated into updated fiscal 2027 guidance and does not represent a material incremental investment this year.

The company’s approach appears to be to scale spending alongside revenue rather than fund an aggressive standalone AI buildout. That supports near-term profitability, though it may also mean the pace of Falcon commercialization depends on execution within a measured investment framework.

Demand, Customers and Pricing

Management described the biopharma spending environment as relatively constructive, with customers continuing to advance pipelines and prioritize efficiency, compliance, and cost reduction. It said interest in Falcon is particularly high because the product addresses those priorities.

Veeva has five Falcon early adopters, with initial go-lives expected this year, based on discussion during the call. Management said these initial deployments are with drug sponsors rather than service providers. It expects Falcon could eventually have applicability for outsourced service providers, but it is concentrating first on sponsors to avoid diffusing development and implementation resources.

One attraction of the model is implementation speed. Management said Falcon does not require the extensive data mapping, system migration, ETL work, or cutover process associated with a conventional enterprise application deployment. The tradeoff is that agentic workflows are newer and require strong controls, training, and guardrails.

Management expects human oversight to remain part of the offering. It compared the need for guardrails around AI agents with the training and controls used for human workers, particularly in regulated life-sciences workflows. The key commercial test will be whether this oversight model can satisfy customers while preserving enough labor savings to support adoption.

Pricing for Falcon has not been finalized. Management said customers want predictable pricing, potentially through enterprise agreements based on company or functional scale, but pricing may rise as Falcon’s capabilities mature. That makes early revenue economics uncertain.

Crossix continued to benefit from healthy pharmaceutical marketing budgets and digital advertising demand, according to management. It also sees AI as a longer-term tailwind because AI-driven engagement channels could increase the need to measure and optimize promotional activity.

What is Veeva Systems’ guidance and outlook?

Management said it raised fiscal 2027 guidance again.

The outlook appears supported by continued Commercial Cloud strength and broad execution in CRM, content, data, and Crossix. At the same time, management signaled that R&D growth may be uneven in the near term as newer products such as EDC, Safety, LIMS, eCOA, and RTSM mature.

For Falcon, management’s immediate objective is product readiness and successful early-adopter deployment rather than a rapid revenue ramp. The company sees substantial customer interest, but it has not included Falcon revenue in its current planning assumptions.

Aspen is also at an early stage. The new horizontal CRM product is being developed with early customers, initially likely including nimble technology start-ups. Management believes there is a market for a lower-complexity, more predictable-priced CRM platform, but it acknowledged that execution remains the core risk.

What Investors Should Watch

1. Falcon Early-Adopter Go-Lives

The first Falcon deployments will be the most important validation point for Veeva’s AI strategy. Investors should watch whether early customers can deploy the product in regulated workflows with sufficient accuracy, oversight, and measurable labor savings.

2. Falcon Pricing and Revenue Model

Management has identified customer demand but has not finalized a durable commercial model. Enterprise subscriptions with predictable pricing could support adoption, but the economics will depend on how Veeva prices improving capabilities and manages AI infrastructure costs.

3. Vault CRM Execution and Top-20 Decisions

Veeva said 12 of the top 20 biopharma companies are using its CRM products, with two remaining commitments expected to be finalized by year-end. Further wins, successful customer go-lives, and evidence of potential Salesforce-related win-backs would strengthen Veeva’s CRM leadership position.

4. R&D Product Transition

EDC, eCOA, RTSM, Safety, and LIMS are central to Veeva’s longer-term R&D growth outlook, but they are still early. Investors should monitor customer implementations and reference customers, particularly in EDC, where deployment cycles are long.

5. Commercial Cloud Breadth

The quarter’s Commercial Cloud growth was broad across CRM, data, content, and Crossix. Sustaining that breadth would reduce reliance on any single product category and support management’s view that its integrated commercial platform is gaining traction.

AlgovestIQ Takeaway

Veeva’s fiscal second quarter was stronger than the headline revenue figure alone suggests. Commercial Cloud subscription growth accelerated to about 13%, CRM execution remained strong, and the company reported broad-based momentum across data, content, measurement, and commercial applications.

The most tangible improvement in the investment case is CRM. Veeva has more than 180 Vault CRM customers live, continued to add major customers, and is presenting a clearer execution contrast against Salesforce implementations that management says have been delayed. The company’s confidence in retaining more than 70% CRM market share and potentially winning back some customers is notable, but it remains a management expectation rather than an achieved outcome.

Falcon could be the more consequential long-term development. Veeva is attempting to extend its role from software provider to provider of AI-enabled labor across life-sciences functions. Its installed base, industry-specific data and applications, and long-standing relationships with business buyers could give it an advantage in a market where customers increasingly want fewer AI vendors.

But Falcon is not yet a financial contributor, and its execution risks are substantial. The company must prove that agents can operate reliably in regulated workflows, establish pricing that customers view as predictable, and scale implementation without undermining margins. Management’s enthusiasm is clear, but so is its acknowledgment that Veeva has not previously operated this type of business.

The central question is whether Veeva can turn its early AI demand into repeatable, high-margin revenue while sustaining growth in its core Commercial and R&D businesses. Successful Falcon go-lives, continued Vault CRM adoption, and evidence that newer R&D products are converting into larger deployments would strengthen that thesis. Delays in those areas, or a slowdown as mature R&D applications give way to earlier-stage products, would be the main counterpoints to monitor.